Why BioLife Solutions (BLFS) Stock Is Up Today

BioLife Solutions (BLFS) is up 5.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is BioLife Solutions’ agreement to be acquired by Repligen in a cash-and-stock transaction that values BioLife at about $31.00 per share, giving investors a clear takeover premium. Sentiment also appears supported by BioLife’s preliminary second-quarter revenue figure, which indicated continued double-digit growth.

Details:

BioLife and Repligen announced a definitive merger agreement on July 22, 2026, with total enterprise value of about $1.5 billion.

Under the deal terms, BioLife stockholders are set to receive $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share.

BioLife disclosed preliminary second-quarter 2026 revenue of about $28.5 million, which was roughly 21% above the year-earlier period.

The buyer said the transaction expands its position in cell therapy and adds BioLife’s biopreservation media business, which likely reinforced the strategic value investors are assigning to BLFS.

Sources:

GlobeNewswire, SEC, BioLife Solutions

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BLFS Insider Trading Activity

$BLFS insiders have traded $BLFS stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $BLFS stock by insiders over the last 6 months:

PARTNERS MASTER FUND, L.P. CASDIN has made 0 purchases and 3 sales selling 1,200,000 shares for an estimated $28,125,000.
KAREN A. FOSTER (Chief Quality and Operations) has made 0 purchases and 4 sales selling 100,418 shares for an estimated $2,021,068.
TROY WICHTERMAN (Chief Financial Officer) sold 588 shares for an estimated $12,195
ABY J. MATHEW (EVP & Chief Scientific Officer) sold 529 shares for an estimated $10,971
TODD BERARD (Chief Marketing Officer) sold 353 shares for an estimated $7,321
SARAH AEBERSOLD (Chief Human Resources Officer) sold 219 shares for an estimated $4,542
SEAN WERNER (Chief Technology Officer) sold 111 shares for an estimated $2,302

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive BLFS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BLFS Hedge Fund Activity

We have seen 90 institutional investors add shares of $BLFS stock to their portfolio, and 65 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CRAMER ROSENTHAL MCGLYNN LLC added 632,812 shares (+inf%) to their portfolio in Q1 2026, for an estimated $12,074,052
VOYA INVESTMENT MANAGEMENT LLC removed 496,937 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,481,557
BANK OF AMERICA CORP /DE/ added 382,776 shares (+73.4%) to their portfolio in Q1 2026, for an estimated $7,303,366
CAPRICORN FUND MANAGERS LTD removed 378,550 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $7,222,733
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 193,093 shares (+19.2%) to their portfolio in Q1 2026, for an estimated $3,684,214
BLACKROCK, INC. added 190,151 shares (+3.2%) to their portfolio in Q1 2026, for an estimated $3,628,081
CITADEL ADVISORS LLC added 146,859 shares (+150.9%) to their portfolio in Q1 2026, for an estimated $2,802,069

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.